World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025
Award Badge
Immunology
USA
2026

D-Index & Metrics

Best Scientists

D-Index
256
Citations
288412
World Ranking
42
National Ranking
27

Immunology

D-Index
260
Citations
292522
World Ranking
3
National Ranking
2

Medicine

D-Index
263
Citations
295948
World Ranking
24
National Ranking
18

Research.com Recognitions

  • 2026 - Research.com Immunology in United States Leader Award
  • 2026 - Research.com Medicine in United States Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Immunology in United States Leader Award
  • 2025 - Research.com Medicine in United States Leader Award
  • 2023 - Research.com Medicine in United States Leader Award
  • 2022 - Research.com Immunology in United States Leader Award
  • 2019 - Szent-Györgyi Prize for Progress in Cancer Research, National Foundation for Cancer Research (NFCR)
  • 2019 - AAI-Steinman Award for Human Immunology Research, American Association of Immunologists
  • 2018 - Albany Medical Center Prize in Medicine and Biomedical Research
  • 2012 - Keio Medical Science Prize, Keio University, Tokyo, Japan
  • 2010 - Karl Landsteiner Memorial Award, American Association of Blood Banks (AABB)
  • 1987 - Member of the National Academy of Medicine (NAM)

Overview

Steven A. Rosenberg is affiliated with the National Institutes of Health in the United States. Their research predominantly focuses on Medicine and Immunology and Microbiology, with subfields including Oncology, Immunology, Molecular Biology, Genetics, and Electrical and Electronic Engineering.

The main topics covered in their work are:

  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • Virus-based gene therapy research
  • Vaccines and immunoinformatics approaches
  • T-cell and B-cell Immunology

Frequent co-authors collaborating with Steven A. Rosenberg include:

  • Frank J. Lowery
  • Paul F. Robbins
  • Jared J. Gartner
  • Stephanie L. Goff
  • Maria R. Parkhurst

Notable publication venues where Rosenberg has frequently contributed are:

  • Regular and Young Investigator Award Abstracts
  • Journal for ImmunoTherapy of Cancer
  • Cancer Research
  • Nature Medicine
  • Cancer Cell

Significant recent papers include:

  • "Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer," 2020, Science
  • "Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer," 2022, New England Journal of Medicine
  • "Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers," 2022, Science
  • "Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors," 2020, Cancer Cell
  • "mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer," 2020, Journal of Clinical Investigation

Several awards have been conferred on Steven A. Rosenberg throughout their career, including:

  • Szent-Györgyi Prize for Progress in Cancer Research, National Foundation for Cancer Research (NFCR), 2019
  • AAI-Steinman Award for Human Immunology Research, American Association of Immunologists, 2019
  • Albany Medical Center Prize in Medicine and Biomedical Research, 2018
  • Keio Medical Science Prize, Keio University, Tokyo, Japan, 2012
  • Karl Landsteiner Memorial Award, American Association of Blood Banks (AABB), 2010
  • Member of the National Academy of Medicine (NAM), 1987

Best Publications

  • Cancer : Principles and Practice of Oncology

    Vincent T. DeVita;Samuel Hellman;Steven A. Rosenberg

  • Cancer regression in patients after transfer of genetically engineered lymphocytes

    Richard A. Morgan;Mark E. Dudley;John R. Wunderlich;Marybeth S. Hughes

  • Cancer immunotherapy: moving beyond current vaccines.

    Steven A Rosenberg;James C Yang;Nicholas P Restifo

  • Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

    Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  • A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

    Steven A. Rosenberg;Michael T. Lotze;Linda M. Muul;Alfred E. Chang

  • A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

    James C. Yang;Leah Haworth;Richard M. Sherry;Patrick Hwu

  • Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

    Steven A. Rosenberg;Michael T. Lotze;Linda M. Muul;Susan Leitman

  • Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

    S A Rosenberg;B S Packard;P M Aebersold;D Solomon

  • T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

    Daniel W Lee;James N Kochenderfer;Maryalice Stetler-Stevenson;Yongzhi K Cui

  • Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

    Richard A Morgan;James C Yang;Mio Kitano;Mark E Dudley

  • Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

    Elizabeth A Grimm;A. Mazumder;H. Z. Zhang;S. A. Rosenberg

  • Adoptive cell transfer as personalized immunotherapy for human cancer.

    Steven A. Rosenberg;Nicholas P. Restifo

  • Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy

    Steven A. Rosenberg;James C. Yang;Richard M. Sherry;Udai S. Kammula

  • A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

    Steven A. Rosenberg;Paul Spiess;Rene Lafreniere

  • High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

    Michael B. Atkins;Michael T. Lotze;Janice P. Dutcher;Richard I. Fisher

  • Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

    Eric Tran;Simon Turcotte;Alena Gros;Paul F. Robbins

  • Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

    Steven A. Rosenberg;James C. Yang;Douglas J. Schwartzentruber;Patrick Hwu

  • T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years

    R. Michael Blaese;Kenneth W. Culver;A. Dusty Miller;Charles S. Carter

  • Adoptive cell transfer: a clinical path to effective cancer immunotherapy

    Steven A. Rosenberg;Nicholas P. Restifo;James C. Yang;Richard A. Morgan

  • Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

    Mark E. Dudley;John R. Wunderlich;James C. Yang;Richard M. Sherry

Frequent Co-Authors

Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Paul F. Robbins
Paul F. Robbins National Cancer Institute
Richard A. Morgan
Richard A. Morgan University of California, Los Angeles
Mark E. Dudley
Mark E. Dudley Novartis (Switzerland)
Suzanne L. Topalian
Suzanne L. Topalian Johns Hopkins University
John R. Wunderlich
John R. Wunderlich National Institutes of Health
James J. Mulé
James J. Mulé University of South Florida
Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
Maria R. Parkhurst
Maria R. Parkhurst National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Immunology often intersects with various healthcare fields, including nursing and mental health. For those interested in complementary pathways, understanding which programs are accessible is crucial. For example, prospective students can find valuable insights on which LPN programs are easiest to get into, helping them start their clinical careers efficiently.

Similarly, nursing professionals may consider advancing through Nurse Practitioner roles. Information on the easiest NP programs to get into can guide applicants seeking streamlined admission processes.

Mental health specialization is another relevant avenue. Online PMHNP programs with strong support systems enhance clinical experience, and resources highlighting online PMHNP programs with clinical placement offer key information for those wanting hands-on learning opportunities.

Cost often remains a major consideration. Students looking for affordable options can explore comprehensive lists of the cheapest psych NP programs to balance budget with quality education.

By reviewing these resources, immunology students and healthcare professionals alike can make informed decisions about advancing their education and careers in related fields.

Best Scientists Citing Steven A. Rosenberg

Trending Scientists

Recently Published Articles